Gadolinium-induced nephrogenic systemic fibrosis.

Richard N Hellman1

  • 1Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. rhellman@iupui.edu

Summary

Nephrogenic systemic fibrosis (NSF) risk in kidney disease patients has decreased due to restricted gadolinium-based contrast (GBC) use. Current protocols limit GBC in severe renal impairment, reducing NSF incidence.